Cargando…

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers

The common chemical and biological properties of antisense oligonucleotides provide the opportunity to identify and characterize chemical class effects across species. The chemical class that has proven to be the most versatile and best characterized is the 2′-O-methoxyethyl chimeric antisense oligo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crooke, Stanley T, Baker, Brenda F, Kwoh, T Jesse, Cheng, Wei, Schulz, Dan J, Xia, Shuting, Salgado, Nelson, Bui, Huynh-Hoa, Hart, Christopher E, Burel, Sebastien A, Younis, Husam S, Geary, Richard S, Henry, Scott P, Bhanot, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112040/ https://www.ncbi.nlm.nih.gov/pubmed/27357629 http://dx.doi.org/10.1038/mt.2016.136

Ejemplares similares

Improvements in the Tolerability Profile of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods
por: Partridge, Wesley, et al.
Publicado: (2021)

The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
por: Crooke, Stanley T., et al.
Publicado: (2017)

The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
por: Crooke, Stanley T., et al.
Publicado: (2018)

Integrated Assessment of the Clinical Performance of GalNAc(3)-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
por: Crooke, Stanley T., et al.
Publicado: (2019)

Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
por: Baker, Brenda F., et al.
Publicado: (2023)

Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2′-O-(2-Methoxyethyl) Modifications
por: Yu, Rosie Z, et al.
Publicado: (2015)

Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency
por: Vickers, Timothy A., et al.
Publicado: (2014)

Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers
por: Watts, Lynnetta M., et al.
Publicado: (2020)

Effective Exon Skipping and Dystrophin Restoration by 2′-O-Methoxyethyl Antisense Oligonucleotide in Dystrophin-Deficient Mice
por: Yang, Lu, et al.
Publicado: (2013)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
por: Burel, Sebastien A., et al.
Publicado: (2016)

Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
por: Liang, Xue-hai, et al.
Publicado: (2017)

Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates
por: Slingsby, Martina H. Lundberg, et al.
Publicado: (2021)

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
por: Nishina, Tomoko, et al.
Publicado: (2015)

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
por: Geary, Richard S., et al.
Publicado: (2015)

Lack of QT Prolongation for 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects
por: Yu, Rosie Z., et al.
Publicado: (2017)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Efficient Synthesis of 2’‐O‐Methoxyethyl Oligonucleotide‐Cationic Peptide Conjugates
por: Halloy, François, et al.
Publicado: (2021)

Solid-Phase Synthesis of Boranophosphate/Phosphorothioate/Phosphate Chimeric Oligonucleotides and Their Potential as Antisense Oligonucleotides
por: Takahashi, Yuhei, et al.
Publicado: (2021)

Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
por: Lima, Walt F., et al.
Publicado: (2014)

Effects of an Antisense Oligonucleotide Inhibitor of C‐Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers
por: Noveck, Robert, et al.
Publicado: (2014)

Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2016)

Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events
por: Partridge, Wesley, et al.
Publicado: (2023)

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies
por: Wu, Chia-Hua, et al.
Publicado: (2019)

Antisense Oligonucleotide Induction of Progerin in Human Myogenic Cells
por: Luo, Yue-Bei, et al.
Publicado: (2014)

COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways
por: Liang, Xue-hai, et al.
Publicado: (2018)

Systematic evaluation of 2′-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro
por: Chen, Suxiang, et al.
Publicado: (2019)

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
por: Viney, Nicholas J., et al.
Publicado: (2020)

The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA
por: Vickers, Timothy A., et al.
Publicado: (2015)

mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
por: Liang, Xue-hai, et al.
Publicado: (2019)

Peptide Conjugates of a 2′-O-Methoxyethyl Phosphorothioate Splice-Switching Oligonucleotide Show Increased Entrapment in Endosomes
por: Hill, Alyssa C., et al.
Publicado: (2023)

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
por: Willmann, Stefan, et al.
Publicado: (2021)

RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery
por: Lima, Walt F., et al.
Publicado: (2016)

Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs
por: Liang, Xue-Hai, et al.
Publicado: (2018)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_upt0qm37om89ud3omc42ivh3be